Brookline Capital Markets Forecasts CLRB Q1 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Brookline Capital Markets issued their Q1 2027 earnings estimates for shares of Cellectar Biosciences in a research note issued on Sunday, July 12th. Brookline Capital Markets analyst K. Dolliver forecasts that the biopharmaceutical company will post earnings per share of ($0.50) for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.34) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.34) EPS.

A number of other equities research analysts have also commented on the stock. Wall Street Zen upgraded shares of Cellectar Biosciences to a “hold” rating in a report on Saturday, June 20th. LADENBURG THALM/SH SH began coverage on shares of Cellectar Biosciences in a research note on Friday, May 15th. They set a “buy” rating for the company. Roth Capital reissued a “buy” rating and issued a $11.00 target price on shares of Cellectar Biosciences in a research note on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Monday, April 20th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Cellectar Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Cellectar Biosciences Price Performance

Shares of CLRB stock opened at $2.63 on Tuesday. The business has a 50-day moving average of $2.81 and a 200 day moving average of $2.99. Cellectar Biosciences has a 1-year low of $2.20 and a 1-year high of $6.52. The stock has a market capitalization of $21.01 million, a PE ratio of -0.39 and a beta of 0.55.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.88) by $0.55.

Institutional Trading of Cellectar Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Cellectar Biosciences by 25.3% during the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 41,704 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Cellectar Biosciences during the 3rd quarter valued at $73,000. Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences in the 3rd quarter worth about $104,000. Sequoia Financial Advisors LLC grew its stake in shares of Cellectar Biosciences by 135.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 14,567 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Cellectar Biosciences by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 3,744 shares in the last quarter. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.